Clinically oriented basic science review: Molecular pathogenesis of skull base tumors

Otology and Neurotology

Volumn 25, Issue 4, 2004, Pages 636-643

  Patel, Nirmal P ^a   Mhatre, Anand N ^a   Lalwani, Anil K ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Otolaryngology   (United States)

Author keywords

Chordoma; Meningioma; Neurofibromatosis type 2; Paraganglioma; Skull base tumors molecular biology; Vestibular schwannoma

Indexed keywords

CARCINOGENESIS; CHORDOMA; CLINICAL FEATURE; GENETIC ANALYSIS; HUMAN; MENINGIOMA; NEURILEMOMA; NEUROFIBROMATOSIS; PARAGANGLIOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SKULL BASE TUMOR; VESTIBULAR SCHWANNOMA; GENE THERAPY; GENETICS; MICROARRAY ANALYSIS; NEUROMA; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

CHORDOMA; GENE THERAPY; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; MENINGIOMA; MICROARRAY ANALYSIS; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PARAGANGLIOMA; SKULL BASE NEOPLASMS;

EID: 4043182868     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200407000-00038     Document Type: Review

References (63)

1. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
2. Zang KD. Cytological and cytogenetical studies on human meningioma. Cancer Genet Cytogenet 1982;6:249-74.
3. Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987;329:246-8.
4. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;75:826.
5. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-21.
6. Gutmann DH, Sherman L, Seftor L, et al. Increased expression of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Hum Mol Genet 1999;8:267-75.
7. Pelton PD, Sherman LS, Rizvi TA, et al. Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene 1998;17:2195-209.
8. McClatchey AI, Saotome I, Mercer K, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998;12:1121-33.
9. Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39:315-22.
10. Sainz J, Huynh DP, Figueroa K, et al. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 1994;3:885-91.
11. Jacoby LB, MacCollin M, Barone R, et al. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer 1996;17:45-55.
12. Bashour AM, Meng JJ, Ip W, et al. The neurofibromatosis type 2 gene product, merlin, reverses the F-actin cytoskeletal defects in primary human Schwannoma cells. Mol Cell Biol 2002;22:1150-7.
13. Schulze KM, Hanemann CO, Muller HW, et al. Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis. Hum Mol Genet 2002; 11:69-76.
14. Welling DB, Lasak KM, Akhmametyeva E, et al. cDNA microarray analysis of vestibular schwannomas. Otol Neurotol 2002;23: 736-48.
15. Lasak JM, Welling DB, Akhmametyeva EM, et al. Retinoblastoma-cyclin- dependent kinase pathway deregulation in vestibular schwannomas. Laryngoscope 2002;112:1555-61.
16. Bruder CE, Hirvela C, Tapia-Paez I, et al. High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Hum Mol Genet 2001;10: 271-82.
17. Bikhazi PH, Lalwani AK, Kim EJ, et al. Germline screening of the NF-2 gene in families with unilateral vestibular schwannoma. Otolaryngol Head Neck Surg 1998;119:1-6.
18. Rey JA, Bello MJ, De Campos JM, Kusak ME, Moreno S. Cytogenetic analysis in human neurinomas. Cancer Genet Cytogenet 1987;28:187-8.
19. Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorogenesis of human acoustic neuroma. Nature 1986;22:644-7.
20. Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, et al. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol 1997;151:1649-54.
21. Gutmann DH, Giordano MJ, Fishback AS, Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 1997;49:267-70.
22. Huynh DP, Mautner V, Baser ME, Stavrou D, Pulst SM. Immunohistochemical detection of schwannomin and neurofibromin in vestibular schwannomas, ependymomas and meningiomas. J Neuropathol Exp Neurol 1997;56:382-90.
23. Warren C, James LA, Ramsden RT, et al. Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation. J Med Genet 2003;40:802-6.
24. Irving RM. The molecular pathology of tumors of the ear and temporal bone. J Laryngol Otol 1998;112:1011-8.
25. Zang KD. Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001;93:207-20.
26. Weber RG, Bostrom J, Wolter M, et al. Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 1997;94:14719-24.
27. Leone PE, Bello MJ, de Campos JM, et al. NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas. Oncogene 1999;18:2231-9.
28. Harada T, Irving RM, Xuereb JH, et al. Molecular genetic investigation of the neurofibromatosis type 2 tumor suppressor gene in sporadic meningioma. J Neurosurg 1996;84:847-51.
29. Wellenreuther R, Waha A, Vogel Y, et al. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab Invest 1997;77: 601-6.
30. Gutmann DH, Donahoe J, Perry A, et al. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000;9:1495-500.
31. Perry A, Cai DX, Scheithauer BW, et al. Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000;59:872-9.
32. Gutmann DH, Hirbe AC, Huang ZY, Haipek CA. The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion. Neurobiol Dis 2001;8: 266-78.
33. Robb VA, Li W, Gascard P, Perry A, Mohandas N, Gutmann DH. Identification of a third Protein 4.1 tumor suppressor, Protein 4. IR, in meningioma pathogenesis. Neurobiol Dis 2003;13:191-202.
34. Heutink P, van der Mey AG, Sandkuijl LA, et al. A gene subject to genomic imprinting and responsible for hereditary paragangliomas maps to chromosome 11q23-qter. Hum Mol Genet 1992;1: 7-10.
35. Mariman EC, van Beersum SE, Cremers CW, van Baars FM, Ropers HH. Analysis of a second family with hereditary non-chromaffin paragangliomas locates the underlying gene at the proximal region of chromosome 11q. Hum Genet 1993;91:357-61.
36. Baysal BE, Ferrell RE, Willett-Brozick JE, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848-51.
37. Baysal BE, Willett-Brozick JE, Taschner PE, Dauwerse JG, Devilee P, Devlin B. A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumor-suppressor region. Eur J Hum Genet 2001;9:121-9.
38. Struycken PM, Cremers CW, Mariman EC, Joosten FB, Bleker RJ. Glomus tumors and genomic imprinting: influence of inheritance along the paternal or maternal line. Clin Otolaryngol 1997;22: 71-6.
39. Hall JG. Genomic imprinting: review and relevance to human diseases. Am J Hum Genet 1990;46:857-73.
40. Niemann S, Steinberger D, Muller U. PGL3, a third, not maternally imprinted locus in autosomal dominant paraganglioma. Neurogenetics 1999;2:167-70.
41. Baysal BE. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends Endocrinol Metab 2003;14:453-459.
42. Renard L, Godfraind C, Boon LM, Vikkula M. A novel mutation in the SDHD gene in a family with inherited paragangliomas-implications of genetic diagnosis for follow up and treatment. Head Neck 2003;25:146-51.
43. Bikhazi PH, Roeder E, Attaie A, Lalwai AK. Familial paragangliomas: the emerging impact of molecular genetics on evaluation and management. Am J Otol 1999;20:639-43.
44. Bikhazi PH, Messina L, Mhatre AN, Goldstein JA, Lalwani AK. Molecular pathogenesis in sporadic head and neck paraganglioma. Laryngoscope 2000;110:1346-8.
45. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 2002;39:178-83.
46. Sano T, H Horiguchi. Von Hippel-Lindau disease. Microsc Res Tech 2003;60:159-64.
47. Poe DS, Tarlov EC, Thomas CB, Kveton JF. Aggressive papillary tumors of temporal bone. Otolaryngol Head Neck Surg 1993;108: 80-6.
48. Tibbs RE Jr., Bowles AP Jr, Raila FA, Fratkin JD, Hutchins JB. Should endolymphatic sac tumors be considered part of the von Hippel-Lindau complex? Pathology case report. Neurosurgery 1997;40:848-55;discussion 855.
49. Richard S, David P, Marsot-Dupuch K, Giraud S, Beroud C, Resche F. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease. Neurosurg Rev 2000;23:1-22;discussion 23-4.
50. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
51. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
52. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
53. Vortmeyer AO, Huang SC, Koch CA, et al. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors. Cancer Res 2000;60:5963-5.
54. Duan DR, Pause A, Burgess WH, et al. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 1995;269;1402-6.
55. Pause A, Lee S, Lonergan KM, Klausner RD. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A 1998;95:993-8.
56. Dalpra L, Malgara R, Miozzo M, et al. First cytogenetic study of a recurrent familial chordoma of the clivus. Int J Cancer 1999;81: 24-30.
57. Miozzo M, Dalpra L, Riva P, et al. A tumor suppressor locus in familial and sporadic chordoma maps to 1p36. Int J Cancer 2000; 87:68-72.
58. Riva P, Dalpra L, Gualandri V, et al. 19p deletion in recurring leiomyosarcoma lesions from the same patient. Cancer Genet Cytogenet 2000;119:102-8.
59. Riva P, Crosti F, Orzan F, et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003;107;493-7.
60. Haeckel C, Krueger S, Kuester D, et al. Expression of cathepsin K in chordoma. Hum Pathol 2000;31:834-40.
61. Jane JA Jr, Helm GA. Gene therapy for skull base tumors. Neurosurg Clin N Am 2000;11:703-16.
62. Tuting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. J Mol Med 1997;75:478-91.
63. Kumar R, Kuniyasu H, Bucana CD, Wilson MR, Fidler IJ. Spatial and temporal expression of angiogenic molecules during tumor growth and progression. Oncol Res 1998;10:301-11.